Acyclovir treatment of varicella-zoster virus meningeal infections and acute kidney injury: a multicentre case series study

• Published in: Infectious diseases (London, England) Vol. 56; no. 10; p. 842
• Main Authors: Contamine, Myriam, Ader, Florence, Lepiller, Quentin, Martha, Benoit, Cagnon-Chapalain, Joséphine, Leturnier, Paul, Frober, Emilie, Bouiller, Kevin, Binquet, Christine, Auvray, Christelle, Piroth, Lionel, Blot, Mathieu
• Format: Journal Article
• Language: English
• Published: England 02.10.2024
• Subjects: Acute Kidney Injury - virology; Acyclovir - administration & dosage; Acyclovir - therapeutic use; Adult; Aged; Antiviral Agents - administration & dosage; Antiviral Agents - therapeutic use; DNA, Viral - cerebrospinal fluid; Female; Herpes Zoster - complications; Herpes Zoster - drug therapy; Herpes Zoster - virology; Herpesvirus 3, Human - drug effects; Herpesvirus 3, Human - genetics; Herpesvirus 3, Human - isolation & purification; Humans; Male; Meningitis, Viral - cerebrospinal fluid; Meningitis, Viral - drug therapy; Meningitis, Viral - virology; Middle Aged; Retrospective Studies; Varicella Zoster Virus Infection - complications; Varicella Zoster Virus Infection - drug therapy; acute kidney injury; acyclovir; Varicella-zoster virus; encephalitis; meningitis
• ISSN: 2374-4243
• DOI: 10.1080/23744235.2024.2355989

Systematic treatment with intravenous acyclovir is usually given when varicella zoster virus (VZV) DNA is isolated in cerebrospinal fluid (CSF), indicating central nervous system (CNS) involvement. Our study aimed to describe therapeutic management and acute kidney injury (AKI) occurrence during acyclovir treatment of VZV infection with CNS involvement. Multicentre, retrospective study including all patients from 2010 to 2022 with VZV DNA in CSF. Patient management and outcomes were compared according to clinical presentation and indications for intravenous acyclovir: i) definite (encephalitis, myelitis or stroke, peripheral nervous system (PNS) with ≥ 2 roots, herpes zoster ≥ 3 dermatomes, immunosuppression), ii) questionable (1 or 2 dermatomes) or iii) no indication (other situations). 154 patients were included (median age 66 (interquartile range 43-77), 87 (56%) males); 60 (39%) had encephalitis, myelitis or stroke, 35 (23%) had PNS involvement, 37 (24%) had isolated meningitis, 14 (9%) had isolated cutaneous presentation, and 8 (5%) had other presentations. Overall, 128 (83%) received intravenous acyclovir for more than 72 h. AKI occurred in 57 (37%) patients. Finally, 42 (27%) and 25 (16%) patients had respectively no or a questionable indication for intravenous acyclovir, while 29 (69%) and 23 (92%) of them received it for more than 72 h, with AKI in 13 (35%) and 13 (52%) patients, respectively. In-hospital mortality was 12% (  = 18), and no deaths were reported in isolated meningitis. Intravenous acyclovir is widely prescribed when VZV DNA is isolated in CSF, regardless of the clinical presentation, with a high rate of AKI. Further studies are needed to better define the value of intravenous acyclovir in isolated VZV meningitis.